KL
KLYG.US Kelyniam Global Inc
- Market cap
- USD 5.06M
- P/E
- -
- P/B
- -
- ROE
- -32.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is KLYG.US undervalued?
Graham numberThe Graham number of Kelyniam Global Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Kelyniam Global Inc fundamental analysis
No fundamental analysis for Kelyniam Global Inc yet.
Kelyniam Global Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Kelyniam Global Inc
Kelyniam Global, Inc., a medical device manufacturing company, engages in the production of custom prosthetics cranial implants utilizing computer aided design, and computer aided manufacturing of advanced medical grade polymers in the United States. The company is also involved in the development, manufacture, and distribution of custom cranial implant for patients requiring the reconstruction of cranial and facial structures. It serves surgeons, health systems, and payors.…
Full company profileKelyniam Global Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Kelyniam Global Inc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.53M | 1.85M | 2.12M | 2.18M | 2.51M | 2.66M | 3.02M | 2.67M | 3.33M | 3.05M | 3.94M |
| Gross Profit | 791K | 1.09M | 1.16M | 1.07M | 1.17M | 2.04M | 2.20M | 2.04M | 1.63M | 2.30M | 3.17M |
| Operating Income | -13.6K | 107K | -7.58K | -103K | 78.2K | 212K | -54.4K | -239K | -628K | -108K | 289K |
| EBITDA | 28.2K | 148K | 7.50K | -367K | 99.3K | 274K | -7.06K | -198K | -996K | -59.2K | 316K |
| Net Income | -13.5K | -72.5K | -15.3K | -358K | 141K | 202K | -97.6K | -218K | -920K | -139K | -234K |
| EPS | 0.00 | 0.00 | 0.00 | -0.01 | 0.01 | 0.01 | 0.00 | -0.01 | -0.02 | 0.00 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 1.30M | 1.17M | 1.25M | 1.52M | 1.31M | 1.43M | 1.71M | 1.63M | 1.77M | 1.75M | 1.80M |
| Total Liabilities | 615K | 558K | 649K | 1.25M | 836K | 738K | 945K | 1.01M | 884K | 939K | 1.08M |
| Shareholders' Equity | 686K | 610K | 605K | 274K | 477K | 693K | 761K | 620K | 884K | 813K | 727K |
| Cash & Short-term Investments | 116K | 199K | 66.4K | 97.5K | 42.7K | - | - | 9.07K | 153K | 105K | 18.0K |
| Total Debt | 348K | 314K | 425K | 675K | 404K | 308K | 560K | 632K | 418K | 509K | 469K |
| Cash Flow | |||||||||||
| Operating Cash Flow | 11.8K | 141K | 15.0K | -239K | 202K | 124K | -31.8K | -95.8K | 104K | -194K | -113K |
| Capital Expenditure | 1.19K | 21.1K | 99.5K | 8.83K | 48.6K | 10.6K | 51.7K | 3.00 | 6.56K | 0.00 | 13.9K |
| Free Cash Flow | 10.6K | 120K | -84.5K | -248K | 153K | 114K | -83.5K | -95.8K | 97.0K | -194K | -127K |
| Ratios | |||||||||||
| ROE | -2.0% | -11.9% | -2.5% | -130.8% | 29.6% | 29.1% | -12.8% | -35.3% | -104.0% | -17.0% | -32.2% |
| ROA | -1.0% | -6.2% | -1.2% | -23.5% | 10.7% | 14.1% | -5.7% | -13.4% | -52.0% | -7.9% | -13.0% |
| Net Profit Margin | -0.9% | -3.9% | -0.7% | -16.4% | 5.6% | 7.6% | -3.2% | -8.2% | -27.6% | -4.5% | -5.9% |
| Debt to Equity | 0.51x | 0.51x | 0.70x | 2.47x | 0.85x | 0.44x | 0.74x | 1.02x | 0.47x | 0.63x | 0.64x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Kelyniam Global Inc dividends
Kelyniam Global Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 2:1 on Mar 5, 2009.
Who owns Kelyniam Global Inc
Ownership data of Kelyniam Global Inc is not available yet.
Kelyniam Global Inc company profile
- Company name
- Kelyniam Global Inc
- Ticker
- KLYG.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Fiscal year end
- December
- Address
- 97 River Road, Canton, CT, United States, 06019
- Phone
- 800 280 8192
- Website
- kelyniam.com
About Kelyniam Global Inc
Kelyniam Global, Inc., a medical device manufacturing company, engages in the production of custom prosthetics cranial implants utilizing computer aided design, and computer aided manufacturing of advanced medical grade polymers in the United States. The company is also involved in the development, manufacture, and distribution of custom cranial implant for patients requiring the reconstruction of cranial and facial structures. It serves surgeons, health systems, and payors. The company was formerly known as Ketner Global Investments, Inc. and changed its name to Kelyniam Global, Inc. in December 2007. Kelyniam Global, Inc. was incorporated in 2005 and is based in Canton, Connecticut.
Kelyniam Global Inc management
6- Mr. Ross BjellaChairman & CEO · born 1962
- Mr. Terrance KurtenbachChief Financial Officer
- Mr. Kris RentonChief Revenue Officer & VP of Operations
- Michael HamblettDirector of Investor Relations
- Mr. James Barrow Esq.General Counsel and Director of Quality & Regulatory
- Dr. Christopher MiruckiChief Medical Officer